The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials
- 1 April 2007
- journal article
- research article
- Published by Wiley in Journal of Thrombosis and Haemostasis
- Vol. 5 (4), 729-737
- https://doi.org/10.1111/j.1538-7836.2007.02427.x
Abstract
Low-molecular-weight heparins (LMWH) have an antitumor effect in vitro and in experimental animal models of malignancy. Retrospective data suggest that it might improve survival in cancer patients.To evaluate the effect of LMWH compared to placebo or no anticoagulant intervention on the survival of cancer patients.We conducted a systematic review of randomized trials specifically evaluating the impact of LMWH on the survival of cancer patients. DATA SOURCES WERE: MEDLINE, EMBASE, HealthSTAR, Cochrane library, gray literature and cross-referencing from reference lists. Data extraction was performed by one reviewer, and accuracy was independently verified by a second reviewer. Meta-analysis was conducted using: (i) odds ratio (OR) and relative risk (RR); (ii) survival rates using censored endpoints; and (iii) hazard ratios (HR).The pooled HR in all patients was 0.83 (95% CI 0.70-0.99; P = 0.03), and in patients with advanced disease it was 0.86 (95% CI 0.74-0.99; P = 0.04), both in favor of the LMWH group. The results of the OR, RR and survival meta-analysis consistently favored the LMWH group. Sensitivity analyses according to tumor type were not conducted, because of a lack of information.LMWH improves overall survival in cancer patients, even in those with advanced disease. Additional trials are required to define the tumor types, disease stages and dosing schedules most likely to provide the greatest survival benefit.Keywords
This publication has 49 references indexed in Scilit:
- Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesisBlood, 2005
- Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cellsBlood, 2005
- Low-Molecular-Weight Heparin and Cancer Survival: Review of the Literature and Pooled Analysis of 1,726 Patients Treated for at Least Three MonthsPathophysiology of Haemostasis and Thrombosis, 2003
- Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomesStatistics in Medicine, 2002
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Coagulation proteases and human cancerBiochemical Society Transactions, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- CANCER INCIDENCE AND MORTALITY IN PATIENTS HAVING ANTICOAGULANT THERAPYThe Lancet, 1964